BMY
$76.14
One Year Performance +16.96%
| Sector | Healthcare | Beta | 0.48 | ETF | No | EPS | 2.82 |
| Industry | Drug Manufacturers—General | Last Div | 2.06 | 52W Range | 53.22-78.61 | Mkt Cap | 162,106,621,952 |
| IPO Since | 1929-07-05 | Exchange | NYSE | PE | 26.97 | Shares | 2,129,059,915 |
Who Has BMY
|
|
|
|
|
|
|
|
|
|
|
Profitability
Profitability Indicators Chart
Profit Margin Chart
| TTM | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability Indicators | ||||||||||||
| Revenue Per Share | 21.33 | 20.54 | 18.83 | 15.33 | 13.82 | 12.63 | 11.63 | 9.93 | 9.58 | 9.97 | 10.55 | 12.5 |
| Earning Per Share | 2.85 | 3.11 | -3.99 | 2.02 | 3.01 | 0.61 | 2.67 | 0.94 | 1.21 | 1.56 | 1.17 | 2.18 |
| Operating Cash Flow Per Share | 7.35 | 7.18 | 6.22 | 4.73 | 3.64 | 3.21 | 1.71 | 1.1 | 1.9 | 2.16 | 4.16 | 2.85 |
| Free Cash Flow Per Share | 6.88 | 6.75 | 5.89 | 4.24 | 3.06 | 2.57 | 0.98 | 0.61 | 1.58 | 1.83 | 3.83 | 2.63 |
| Book Value Per Share | 14.34 | 15.95 | 16.75 | 30.26 | 8.59 | 7.14 | 9.68 | 8.56 | 8.96 | 9.22 | 8.16 | 9.39 |
| Gross Profit Margin % | 79.62 | 78.57 | 72.31 | 69.1 | 70.98 | 70.8 | 74.54 | 76.39 | 75.24 | 71.81 | 73.84 | 73.65 |
| Operating Profit Margin % | 22.65 | 15.91 | 5.12 | 22.62 | 22.69 | 16.61 | 23.36 | 10.45 | 10.79 | 17.89 | 22.31 | 31.29 |
| Tax Rate % | 13.6 | 13.39 | -30.91 | 30.45 | 17.11 | 81 | 23.8 | 21.47 | 14.78 | 10.76 | -6.88 | 24.65 |
| Net Profit Margin % | 13.35 | 15.12 | -21.2 | 13.15 | 21.81 | 4.85 | 22.94 | 9.45 | 12.62 | 15.64 | 11.12 | 17.46 |
| Profitability Growth (YoY) | ||||||||||||
| Revenue Growth % | - | 9.09 | 62.62 | 15.89 | 8.59 | 6.94 | 17.31 | 4.29 | -3.09 | -7.01 | -17.05 | 9.03 |
| EPS Growth % | - | 177.8 | -362.14 | -30.1 | 388.58 | -77.41 | 184.79 | -21.91 | -21.81 | 30.77 | -47.16 | 19.57 |
| Operating Cash Flow Growth % | - | 15.34 | 74.19 | 35.81 | 12.61 | 85.09 | 55.57 | -41.8 | -11.2 | -48.93 | 43.41 | 7.77 |
| Free Cash Flow Growth % | - | 14.55 | 83.92 | 44.94 | 18.22 | 158.1 | 61.56 | -61.4 | -12.83 | -52.95 | 42.92 | 9.98 |
| BVPS Growth % | - | -4.8 | -44.65 | 252.21 | 20.38 | -26.27 | 13.12 | -4.52 | -2.76 | 13 | -13.09 | 2.32 |
| Compound Annual Growth Rate Chart (CAGR) | 10Y CAGR | 7Y CAGR | 5Y CAGR | 3Y CAGR | ||||||||
| Revenue Per Share Growth % (CAGR) | - | 6.89 | 10.94 | 10.21 | 10.24 | |||||||
| Earning Per Share Growth % (CAGR) | - | 10.27 | 18.64 | 38.51 | 15.47 | |||||||
| Operating Cash Flow Per Share Growth % (CAGR) | - | 5.61 | 30.73 | 17.47 | 14.93 | |||||||
| Free Cash Flow Per Share Growth % (CAGR) | - | 5.83 | 40.97 | 21.3 | 16.76 | |||||||
| Book Value Per Share Growth % (CAGR) | - | 6.93 | 9.3 | 17.44 | -19.22 |
BMY News Today
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.
Market Watch 2022-05-26 14:20:00
Bristol Myers Squibb Vs. AbbVie: Who Better Fits Our Barbell?
Both Bristol Myers Squibb and AbbVie spark interest for income- and value-oriented investors. You will see why we favor AbbVie as a better fit for our barbell strategy to build an enduring portfolio for an early retirement.
Seeking Alpha 2022-05-25 13:37:02
Michael Burry Says 2022 Is a ‘Plane Crash.' Here's What the Legendary Investor Is Betting On.
Michael Burry is back on Twitter, although his first tweet upon his return is not very supportive of current market conditions. The post Michael Burry Says 2022 Is a ‘Plane Crash.
InvestorPlace 2022-05-24 15:43:07
3 Health Care Stocks To Watch Right Now
Could these health care stocks be safe bets in the stock market today?
Stockmarketcom 2022-05-20 12:30:00
3 Stocks Up 25% to 65% That Are Still Smart Buys
These high-flying stocks could continue soaring.
The Motley Fool 2022-05-18 11:44:25
